SGLT2 inhibitors increase endothelial VE-cadherin level reduced by 25-hydroxycholesterol
Background and Aims: The exact mechanism of beneficial effects of SGLT2 inhibitors (empagliflozin-empa, canagliflozin-cana, dapagliflozin-dapa) in patients with cardiovascular diseases remains not fully understood. In our previous studies we have shown that SGLT2 inhibitors significantly improve endothelial integrity interrupted by 25-hydroxychoelsterol (25-OHC). The aim of this study was to assess whether SGLT2 inhibitors affect VE-cadherin level, the most important endothelial-specific protein that maintains endothelial barrier functions. (Source: Atherosclerosis)
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: A. Pawlos, P. Gorzelak-Pabi ś, Ł. Markiewicz, E. Woźniak, A. Piastowska-Ciesielska, M. Broncel Source Type: research
SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome
CONCLUSIONS: Our study for the first time demonstrates that CANA exerts a protective effect on vascular calcification at least partially via suppressing NLRP3 signaling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for vascular calcification.PMID:37523743 | DOI:10.1093/cvr/cvad119 (Source: Cell Research)
Source: Cell Research - July 31, 2023 Category: Cytology Authors: An Chen Zirong Lan Li Li Luting Xie Xiaoyu Liu Xiulin Yang Siyi Wang Qingchun Liang Qianqian Dong Liyun Feng Yining Li Yuanzhi Ye Mingwei Fu Lihe Lu Jianyun Yan Source Type: research
SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome
CONCLUSIONS: Our study for the first time demonstrates that CANA exerts a protective effect on vascular calcification at least partially via suppressing NLRP3 signaling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for vascular calcification.PMID:37523743 | DOI:10.1093/cvr/cvad119 (Source: Atherosclerosis)
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: An Chen Zirong Lan Li Li Luting Xie Xiaoyu Liu Xiulin Yang Siyi Wang Qingchun Liang Qianqian Dong Liyun Feng Yining Li Yuanzhi Ye Mingwei Fu Lihe Lu Jianyun Yan Source Type: research
A surfactant-based quasi-hydrophobic deep eutectic solvent for dispersive liquid-liquid microextraction of gliflozins from environmental water samples using UHPLC/fluorescence detection
Talanta. 2023 Jul 22;266(Pt 1):124950. doi: 10.1016/j.talanta.2023.124950. Online ahead of print.ABSTRACTDespite the anticipated exceptional properties of deep eutectic solvents (DES) in microextraction techniques, their self-aggregation behaviour has only been sporadically studied in the previous literature. In the presented study, a novel surfactant-based quasi-hydrophobic deep eutectic solvent (DES) is synthesized and utilized in dispersive liquid-liquid microextraction (DLLME) of three gliflozins in environmental water samples as a proof-of-concept examples. The synthesized DES is composed of benzalkonium chloride (BZK...
Source: Talanta - July 31, 2023 Category: Chemistry Authors: Azza H Rageh Fatma A M Abdel-Aal Sherien A Farrag Al-Montaser Bellah H Ali Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis
CONCLUSION: The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies.PMID:37499149 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - July 27, 2023 Category: Complementary Medicine Authors: GuangZhi Li Dongmei Zhang Jie Ni Shizhen Wang Source Type: research
Molecules, Vol. 28, Pages 5668: Antibacterial Activity and Mechanism of Canagliflozin against Methicillin-Resistant Staphylococcus aureus
In conclusion, canagliflozin exhibits antibacterial activity against MRSA by affecting bacterial metabolism, inhibiting its biofilm formation, distorting the bacterial cell wall, and altering the gene expression of biofilm formation and its virulence. Our study reveals the antibacterial activity of canagliflozin against MRSA, providing a new reference for treating diabetic foot infections. (Source: Molecules)
Source: Molecules - July 26, 2023 Category: Chemistry Authors: Siyao Gu Bing Fan Fang Wan Tong Gao Yuanyuan Qi Jin Zhou Yaou Zhang Dayong Gu Weidong Xie Tags: Article Source Type: research
Comparative effectiveness of sodium ‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction
ConclusionsCompared with canagliflozin or dapagliflozin use, empagliflozin use was associated with decreased risk of HF-related and all-cause hospitalizations. Compared with canagliflozin, dapagliflozin was associated with a reduced risk of HF-related and all-cause hospitalizations. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 18, 2023 Category: Drugs & Pharmacology Authors: Munaza Riaz,
Steven M. Smith,
Eric A. Dietrich,
David E. Winchester,
Jingchuan Guo,
Haesuk Park Tags: RESEARCH ARTICLE Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Medicina (Kaunas). 2023 Jun 12;59(6):1136. doi: 10.3390/medicina59061136.ABSTRACTType 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established cardiovascular benefits, and its class members h...
Source: Medicina (Kaunas) - June 28, 2023 Category: Universities & Medical Training Authors: Ioana-Cristina Bica Roxana Adriana Stoica Teodor Salmen Andrej Jane ž Špela Volčanšek Djordje Popovic Emir Muzurovic Manfredi Rizzo Anca Pantea Stoian Source Type: research
